Table 1 Demographics and resistance profiles of clinical isolates utilized in the study.
Patient No. | Isolate No. | Sex (M/F) | Age (years) | Weight (kg) | BMI (kgm^2) | FEV1 Pred | Bacteria | Resistance Profiles |
|---|---|---|---|---|---|---|---|---|
1 | 1 | F | 57 | 60.6 | 22.5 | 39 | Pseudomonas aeruginosa | NR |
2 | 2 | M | 24 | 72 | 25.3 | 50 | Staphylococcus aureus | Clindamycin, Erythromycin R |
3 | 3 | M | 50 | 57 | 19.3 | 43 | Achromobacter xylosoxidans | Gentamicin, Meropenem, Tobramycin R; Imipenem, Ciprofloxacin I |
4 | 4A | F | 35 | 62 | 22.4 | 87 | Staphylococcus aureus | NR |
| Â | 4B | Â | Â | Â | Â | Â | Pseudomonas aeruginosa (muc) | NR |
| Â | 4C | Â | Â | Â | Â | Â | Pseudomonas aeruginosa | Tobramycin, Gentamicin R |
5 | 5 | F | 44 | 59 | 22 | 73 | Pseudomonas aeruginosa (muc) | Amikacin, Gentamicin, Meropenem, Ciprofloxacin, Tobramycin R |
6 | 6 | F | 40 | 57 | 20.9 | 52 | Pseudomonas aeruginosa (muc) | Gentamicin, Tobramycin R |
7 | 7 | M | 37 | 52.5 | 19.3 | 28 | Pseudomonas aeruginosa (muc) | NR |
8 | 8 | M | 27 | 62 | 18.7 | 48 | Staphylococcus aureus | Clindamycin, Erythromycin, Cloxacillin R |
9 | 9A | F | 31 | 40.5 | 18.2 | 55 | Pseudomonas aeruginosa (muc) | NR |
| Â | 9B | Â | Â | Â | Â | Â | Pseudomonas aeruginosa | Meropenem R; Ciprofloxacin, Gentamicin I |
